Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide.
Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology. Although HHV-8 (human herpesvirus type 8) has been suggested as a possible etiologic agent in a subpopulation of cases, appropriate treatment of the HHV-8 infection has not produced regression of the disease. Additionally, other treatment modalities, including steroids and various regimens of chemotherapy, do not consistently provide good control of the disease. Clinical signs and symptoms of the disease are primarily mediated by cytokines, especially interleukin-6 (IL-6). We report a case of multicentric Castleman's disease that responded dramatically to single agent thalidomide. A powerful cytokine disruptor, thalidomide may have good therapeutic efficacy in treating MCD and related cytokine-mediated disorders.
Lee
Fa-Chyi
FC
Department of Internal Medicine, Division of Hematology/Oncology, University of New Mexico, 900 Camino de Salud, Albuquerque, NM 87131, USA. flee@salud.umn.edu
Merchant
Shakil H
SH
D000328:Adult; D000740:Anemia; D000914:Antibodies, Viral / Q000097:blood; D001365:Axilla; D001706:Biopsy; D005871:Castleman Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D016207:Cytokines / Q000502:physiology; D005260:Female; D019288:Herpesvirus 8, Human / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015850:Interleukin-6 / Q000502:physiology; D007958:Leukocyte Count; D008198:Lymph Nodes / Q000473:pathology; D008206:Lymphatic Diseases / Q000473:pathology; D010996:Pleural Effusion; D013792:Thalidomide / Q000627:therapeutic use*; D013921:Thrombocytopenia; D014057:Tomography, X-Ray Computed; D019210:Troponin I / Q000097:blood
D000914:Antibodies, Viral; D016207:Cytokines; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D019210:Troponin I; D013792:Thalidomide